
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Amedisys Inc (AMED)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: AMED (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Year Target Price $96.17
Year Target Price $96.17
0 | Strong Buy |
1 | Buy |
9 | Hold |
0 | Under performing |
1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.56% | Avg. Invested days 51 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.21B USD | Price to earnings Ratio 36.13 | 1Y Target Price 97.38 |
Price to earnings Ratio 36.13 | 1Y Target Price 97.38 | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 82.15 - 98.95 | Updated Date 06/29/2025 |
52 Weeks Range 82.15 - 98.95 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.71 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.79% | Operating Margin (TTM) 10.11% |
Management Effectiveness
Return on Assets (TTM) 6.36% | Return on Equity (TTM) 7.15% |
Valuation
Trailing PE 36.13 | Forward PE 21.37 | Enterprise Value 3381487345 | Price to Sales(TTM) 1.35 |
Enterprise Value 3381487345 | Price to Sales(TTM) 1.35 | ||
Enterprise Value to Revenue 1.43 | Enterprise Value to EBITDA 14.06 | Shares Outstanding 32819600 | Shares Floating 32175060 |
Shares Outstanding 32819600 | Shares Floating 32175060 | ||
Percent Insiders 1.96 | Percent Institutions 93.03 |
Analyst Ratings
Rating 2.91 | Target Price 96.17 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 9 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Amedisys Inc

Company Overview
History and Background
Amedisys Inc. was founded in 1982. Initially focused on providing home healthcare services in Louisiana, it expanded through acquisitions and organic growth, becoming a leading national provider of home health, hospice, and personal care services. Amedisys offers care to a broad range of patients needing recovery and long-term support.
Core Business Areas
- Home Health: Provides skilled nursing, therapy services, and home health aides to patients in their homes. This segment is focused on helping patients recover from illness or injury and manage chronic conditions.
- Hospice: Offers palliative care and support to patients with terminal illnesses and their families. This segment focuses on providing comfort and improving the quality of life for patients nearing the end of life.
- Personal Care: Provides non-medical assistance with activities of daily living, such as bathing, dressing, and meal preparation. This segment serves patients who need help maintaining their independence at home.
Leadership and Structure
The leadership team includes Chris Gerard (President & CEO), Scott Ginn (Chief Financial Officer), and members for each division. The organizational structure is based on the three core service lines: Home Health, Hospice, and Personal Care, with centralized support functions.
Top Products and Market Share
Key Offerings
- Home Health Services: Includes skilled nursing, physical therapy, occupational therapy, speech therapy, and medical social services. Amedisys is a major player in this market with competitors such as LHC Group (LHCG) and Enhabit (EHAB). Specific market share for individual services is difficult to isolate.
- Hospice Care: Encompasses palliative care, symptom management, emotional support, and spiritual care for terminally ill patients and their families. Key competitors include Gentiva and Compassus. Amedisys holds a significant share of the hospice market, but precise figures vary regionally.
- Personal Care Services: Provides assistance with activities of daily living (ADLs) such as bathing, dressing, grooming, and meal preparation. Competitors in this sector include private-pay agencies and smaller regional providers. Market share data for personal care services is highly fragmented.
Market Dynamics
Industry Overview
The home health and hospice industry is experiencing growth due to the aging population, increasing prevalence of chronic diseases, and a shift towards value-based care. Technological advancements and regulatory changes are also shaping the industry landscape.
Positioning
Amedisys is a leading provider of home health and hospice care, distinguished by its national scale, comprehensive service offerings, and focus on quality and patient outcomes. Its competitive advantages include a strong brand reputation, established relationships with referral sources, and investment in technology to improve care delivery.
Total Addressable Market (TAM)
The TAM for home health and hospice care in the US is estimated to be several hundred billion dollars annually. Amedisys is well-positioned to capture a significant portion of this market with its diversified service offerings and expanding geographic footprint.
Upturn SWOT Analysis
Strengths
- National Scale
- Comprehensive Service Offerings
- Strong Brand Reputation
- Established Relationships with Referral Sources
- Investment in Technology
Weaknesses
- Labor Shortages
- High Turnover Rates
- Regulatory Compliance Challenges
- Reimbursement Pressures
- Integration Risks from Acquisitions
Opportunities
- Aging Population
- Increasing Prevalence of Chronic Diseases
- Shift Towards Value-Based Care
- Expansion into New Geographies
- Partnerships with Healthcare Providers
Threats
- Competition from Other Home Health and Hospice Providers
- Changes in Government Reimbursement Policies
- Rising Labor Costs
- Increased Regulatory Scrutiny
- Economic Downturn
Competitors and Market Share
Key Competitors
- LHCG
- EHAB
- GNTVA (Private)
- COMPASSUS (Private)
Competitive Landscape
Amedisys competes with other national and regional home health and hospice providers. Its advantages include its scale, comprehensive service offerings, and strong brand reputation. Disadvantages include labor shortages and regulatory compliance challenges.
Major Acquisitions
Contessa Health
- Year: 2021
- Acquisition Price (USD millions): 250
- Strategic Rationale: Expanded Amedisys' home-based acute care capabilities, allowing them to offer hospital-at-home services.
Growth Trajectory and Initiatives
Historical Growth: Amedisys has experienced significant growth through acquisitions and organic expansion. Revenue has steadily increased over the past decade, driven by demand for home health and hospice services.
Future Projections: Future growth is expected to be driven by the aging population and the increasing prevalence of chronic diseases, and is expected to continue increasing at a modest rate. Analyst estimates vary based on market conditions and company performance.
Recent Initiatives: Recent initiatives include investments in technology to improve care delivery, expansion into new geographies through acquisitions, and partnerships with healthcare providers to improve patient outcomes.
Summary
Amedisys is a strong player in the home health and hospice market, benefiting from the aging population and increasing demand for in-home care. Its national scale and comprehensive services provide a competitive edge, but the company faces challenges related to labor shortages and regulatory compliance. Strategic acquisitions and investments in technology should support future growth; however, the cost will add risk to the financials. Investors should watch how they integrate these purchases and how those impact revenue.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
- Company Website
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice, and investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amedisys Inc
Exchange NASDAQ | Headquaters Baton Rouge, LA, United States | ||
IPO Launch date 1994-08-17 | President, CEO & Director Mr. Richard M. Ashworth | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 19000 | Website https://www.amedisys.com |
Full time employees 19000 | Website https://www.amedisys.com |
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.